These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 12722879)

  • 1. Aromatase inhibitors for treatment of postmenopausal patients with breast cancer.
    Tamaki Y; Miyoshi Y; Kim SJ; Tanji Y; Taguchi T; Noguchi S
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):193-201. PubMed ID: 12722879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients.
    Pritchard KI
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4356s-4359s; discussion 4411s-4412s. PubMed ID: 11916225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical differences among the aromatase inhibitors.
    Ligibel JA; Winer EP
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):473S-9S. PubMed ID: 12538503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    Ingle JN
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
    Monnier A
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1355-9. PubMed ID: 17069521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current status and prospectives of aromatase inhibitors in the treatment of advanced breast cancer].
    Boccardo F
    Minerva Ginecol; 1998 Mar; 50(3):51-63. PubMed ID: 9595916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are aromatase inhibitors superior to antiestrogens?
    Howell A; Buzdar A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
    Buzdar A; Chlebowski R; Cuzick J; Duffy S; Forbes J; Jonat W; Ravdin P
    Curr Med Res Opin; 2006 Aug; 22(8):1575-85. PubMed ID: 16870082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of the new aromatase inhibitors in the treatment of breast cancer.
    Sulkes A
    Isr Med Assoc J; 2005 Apr; 7(4):257-61. PubMed ID: 15847208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art].
    Azria D; Lemanski C; Zouhair A; Gutowski M; Belkacémi Y; Dubois JB; Romieu G; Ozsahin M
    Cancer Radiother; 2004 Jun; 8(3):188-96. PubMed ID: 15217586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.